Autosomal Dominant Nonsyndromic Hearing Loss 53

1. Disease Information

Overview. DFNA53 designates an autosomal dominant, nonsyndromic (isolated) sensorineural hearing loss locus mapped to human chromosome 14q11.2–q12 in a single large, multigenerational Chinese family. The phenotype is postlingual (onset in adolescence/the second decade of life), begins as high-frequency hearing loss, and progresses to involve all frequencies, reaching a profound degree by the fourth–fifth decade of life (Yan et al., 2006, PMID:15958501; Aldè et al. 2023, PMC:PMC10296186).

"post-lingual, high frequency hearing loss that progresses to involve all frequencies" — Yan D et al., J Med Genet 2006;43(2):170-174.

"HL is initially mild and limited to high frequencies but gradually involves all frequencies and progresses to a profound degree by the 4th/5th decade of life." — Aldè et al., Audiology Research 2023 (DFNA locus table entry for DFNA53).

Key identifiers: | Resource | Identifier | |---|---| | OMIM | #609965 — DEAFNESS, AUTOSOMAL DOMINANT 53; DFNA53 | | MONDO | MONDO:0012380 | | MedGen | C1864957 (NCBI GTR: C1864957) | | GARD (NIH rare disease) | GARD ID 9934 | | Locus | 14q11.2–q12 | | Gene | Not identified |

Synonyms: Deafness, autosomal dominant 53; autosomal dominant nonsyndromic deafness 53; autosomal dominant nonsyndromic hearing loss 53.

Data provenance. All disease-level information available for DFNA53 derives from a single aggregated genetic-mapping study of one family (a case series/pedigree study), not from EHR-derived or population-registry data. There is no disease registry, no epidemiologic surveillance record, and no subsequent replication cohort.

2. Etiology

• Disease causal factor: Presumed to be a single dominant (heterozygous) germline variant in an as-yet-unidentified gene within the 14q11.2–q12 interval, based on autosomal dominant segregation with a maximum multipoint LOD score of 5.4 at marker D14S1280 (PMID:15958501).
• Genetic risk factors: Inheriting the disease haplotype from an affected parent; no specific variant, susceptibility locus, or modifier gene has been reported.
• Environmental risk factors: None reported or investigated for this locus; no environmental co-factor has been described in the single published family.
• Protective factors: Not studied.
• Gene–environment interaction: Not studied. No data exist to assess this axis for DFNA53 specifically.

Candidate genes within the mapped interval that were explicitly excluded by direct screening in the original family are: - COCH (the DFNA9 gene, HGNC:2180) — the DFNA53 critical region contains the COCH locus, but sequencing did not identify a causative variant. - BOCT / SLC22A17 - EFS - HSPC156 / STXBP6

"the critical region for DFNA53 contains the gene for DFNA9 [COCH] but does not overlap with the regions for DFNB5, DFNA23, or DFNB35... screening of the COCH gene, BOCT (SLC22A17), EFS, and HSPC156 (STXBP6) within the DFNA53 interval did not identify the cause for deafness in this family" (Yan et al. 2006, PMID:15958501).

3. Phenotypes

Because only one family has been reported, phenotype "frequency" data (e.g., % of patients with a feature) does not exist in the population-genetics sense — the figures below describe the single pedigree's clinical course as reported.

• Phenotype type: Sensorineural hearing impairment (a clinical sign/laboratory-audiometric abnormality), not a syndromic constellation — the entry is explicitly "nonsyndromic," meaning no other organ system involvement was reported in the affected family.
• Severity/progression: Progressive, sloping-to-flat/profound audiometric configuration, consistent with many other DFNA loci (Aldè et al. 2023, PMC10296186).
• Vestibular function: The original 2006 report does not describe vestibular testing or vestibular symptoms. A downstream NCBI GTR/MedGen record lists "abnormal vestibular function" as an associated clinical feature for this condition, but this could not be traced to a specific statement in the primary Yan et al. paper during this search — flag this as an unverified, database-level tag rather than a confirmed primary-literature finding, and it should not be curated as evidence without independent confirmation.
• Quality of life impact: Not studied for this specific family; no disease-specific QOL instrument data exist.

4. Genetic/Molecular Information

• Causal gene: Unknown. No gene has been identified for DFNA53 in the ~20 years since the locus was mapped (confirmed by the current hereditaryhearingloss.org DFNA locus table, which lists DFNA53 as "gene unknown," and by the absence of any subsequent primary literature identifying a causal gene).
• Locus: 14q11.2–q12, a 9.6 cM interval bounded by microsatellite markers D14S581 and D14S1021, with peak linkage (multipoint LOD 5.4) at D14S1280 (PMID:15958501).
• Variant classification/type/allele frequency/somatic-vs-germline/functional consequence: Not applicable — no variant has been reported.
• Modifier genes, epigenetic information, chromosomal abnormalities: None reported.
• Relationship to other loci on 14q: Four other deafness loci map to the long arm of chromosome 14 — DFNA9 (COCH, sits inside the DFNA53 critical region but was excluded as causal), DFNA23, DFNB5, and DFNB35 — but the DFNA53 interval does not overlap the latter three (PMID:15958501). This makes DFNA53 genetically and physically distinct from its chromosome-14 neighbors even though it spatially contains the COCH gene.

5. Environmental Information

No environmental factors, lifestyle factors, or infectious agents have been reported or investigated in connection with DFNA53. As a monogenic, single-family, autosomal dominant mapping result, there is no literature addressing gene–environment modulation of this specific locus.

6. Mechanism / Pathophysiology

No mechanism can be constructed for DFNA53 with any specificity, because the causal gene is unknown. A causal chain cannot be drawn beyond the top-level genetic statement, and any lower step would be an inference from the general biology of nonsyndromic hearing loss rather than a demonstrated fact about this locus. Presenting a plausible-looking pathway here would misrepresent the state of evidence, so only the following is offered:

1. A dominant germline variant at an unidentified gene in 14q11.2–q12 is inferred to disrupt inner-ear (most likely cochlear) structure or function — inferred, not demonstrated, from the clinical phenotype (progressive high-frequency-onset SNHL) by analogy to other DFNA loci with a similar audiometric trajectory.
2. This putative dysfunction is inferred to initially and preferentially affect basal-turn (high-frequency-coding) cochlear hair cells or their supporting structures, given the high-frequency-first audiometric pattern — again inferred by analogy, not shown directly for this locus.
3. Progression to pantonal, profound loss by the 4th–5th decade suggests a slowly progressive degenerative process rather than a static congenital lesion — inferred from the clinical course alone.

No molecular pathway, cellular process, protein dysfunction, metabolic change, immune involvement, tissue-damage mechanism, biochemical abnormality, epigenetic change, or any -omics profiling (transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial) has been reported for DFNA53, because the causal gene — and therefore any tissue or cellular substrate to study — has never been identified. No GO or CL term can be responsibly assigned to a specific mechanistic step for this entry without fabricating specificity the source does not support.

7. Anatomical Structures Affected

• Organ level: Inner ear (cochlea) — the only organ system reported as affected, consistent with the "nonsyndromic" designation (no other organ involvement reported). Body system: auditory/sensory (and, per the caveated GTR vestibular tag in §3, possibly vestibular — unconfirmed).
• Anatomical term (UBERON): UBERON:0001846 (cochlea) is the most specific defensible anatomical anchor, since no cell-type-specific or subcellular-level finding has been reported.
• Tissue/cell/subcellular level: No specific cell population (e.g., outer vs. inner hair cells, stria vascularis, spiral ganglion) or organelle has been implicated by any study — this would need to be inferred from a mechanism that does not yet exist for this locus (see §6).
• Laterality: Bilateral, based on standard DFNA convention and the "sensorineural hearing impairment" HPO/GTR coding (bilateral is the default assumption for nonsyndromic genetic SNHL loci; not separately confirmed as bilateral vs. asymmetric in the primary paper's abstract).

8. Temporal Development

• Onset: Postlingual, adolescence/second decade of life (PMID:15958501; Aldè et al. 2023).
• Onset pattern: Insidious, not acute.
• Progression: Progressive — initially mild, limited to high frequencies; gradually involves all frequencies; reaches profound severity by the 4th–5th decade of life (Aldè et al. 2023, PMC10296186).
• Disease course pattern: Progressive, not episodic or relapsing-remitting; no data on plateaus or stable phases.
• Remission: None reported (progressive sensorineural hearing loss of this type is not expected to remit).
• Critical periods: Not established — no data on a window during which intervention alters outcome, though for any progressive postlingual SNHL, earlier identification of decline would generally be presumed clinically useful (a general inference, not DFNA53-specific evidence).

9. Inheritance and Population

• Epidemiology: No prevalence or incidence estimate exists for DFNA53 specifically. It has been reported in exactly one family; DFNA loci collectively account for only a minority (roughly 20%) of hereditary nonsyndromic hearing loss, but no locus-specific frequency figure is available for DFNA53 (general DFNA-class context from Aldè et al. 2023, not DFNA53-specific).
• Inheritance pattern: Autosomal dominant, based on classic segregation of the phenotype with the 14q11.2-q12 haplotype across multiple generations, with a maximum multipoint LOD score of 5.4 (PMID:15958501).
• Penetrance: Not explicitly quantified in the abstract; the family structure implies high (if not complete) penetrance sufficient to generate a LOD score of 5.4, but no numeric penetrance estimate has been published.
• Expressivity, anticipation, germline mosaicism, founder effects, consanguinity, carrier frequency: None reported/applicable — these require either multiple pedigrees or population data, neither of which exists for this single-family locus.
• Population demographics: The single reported family is Chinese (Han Chinese, presumptively, based on recruitment context, though ethnicity beyond "Chinese family" is not further specified in the abstract). No other population, geographic distribution, sex ratio, or age-distribution data exist.

10. Diagnostics

No DFNA53-specific diagnostic test, biomarker, imaging finding, or histopathology has been described (there is no known gene to target with a single-gene or panel-based clinical test). General, non-locus-specific guidance applicable to any postlingual progressive autosomal dominant SNHL family would include:

• Audiometry: Pure-tone audiometry to document the sloping-to-flat/pantonal progressive configuration — the primary phenotyping tool used in the original family study.
• Genetic testing (general, not DFNA53-specific): Because no causal gene is known, a clinical multi-gene hereditary hearing loss panel or exome/genome sequencing would not currently include a targeted DFNA53 assay; family-specific linkage analysis (as performed in the original 2006 study, using markers such as D14S581, D14S1280, D14S1021) would be the only way to test for co-segregation with this specific chromosomal region in a new large family, but this is a research approach, not a clinical diagnostic offering.
• Differential diagnosis: Other chromosome 14 DFNA loci in the region (DFNA9/COCH) should be excluded by direct gene sequencing before considering a novel-locus mapping study, exactly as was done in the original report.
• Screening: No population or newborn screening applies to this ultra-rare, single-family locus.

11. Outcome/Prognosis

• Survival/mortality: Not applicable — nonsyndromic hearing loss does not affect survival; no mortality data exist or would be expected.
• Morbidity/function: Progressive profound sensorineural hearing loss by the 4th–5th decade would be expected to significantly affect communication function and quality of life, by general analogy to other progressive DFNA phenotypes, but no disease-specific functional-outcome or QOL data have been published for DFNA53.
• Complications: None reported beyond the hearing loss itself (nonsyndromic — no other organ complications documented).
• Prognostic factors/biomarkers: None established.

12. Treatment

No DFNA53-specific treatment or gene-targeted therapy exists (there is no identified gene to target). Management would follow the standard, non-locus-specific approach to progressive sensorineural hearing loss:

• Amplification: Hearing aids as high-frequency loss becomes functionally significant — NCIT term candidate: NCIT:C-hearing aid device concept would be bound as a device, not a TreatmentTerm action, per standard NCIT device-vs-action handling (analogous devices are typically bound via the clinical-action + qualifiers pattern, e.g., "hearing aid fitting" bound to a general audiologic-rehabilitation action term with the device carried as a qualifier).
• Cochlear implantation: Would be the standard intervention once loss progresses to a profound, aid-non-responsive level, following the general clinical pathway used for other progressive genetic SNHL loci — NCIT:C15329 (Surgical Procedure) is the appropriate clinical-action anchor for the implantation itself, per standard dismech convention for device-based interventions.
• Audiologic rehabilitation/speech-language therapy: Standard supportive care for progressive hearing loss — NCIT:C15302 (Physical Therapy)/NCIT:C159273 (Speech Language Therapy) analogs, as used generically across other DFNA entries.
• Genetic counseling: NCIT:C15240 (Genetic Counseling), given the confirmed autosomal dominant inheritance and 50% offspring recurrence risk (GARD summary).
• Gene therapy, RNA-based therapy, targeted/precision therapy: Not applicable — no target gene exists to develop a molecular therapeutic against.
• Clinical trials: No DFNA53-specific trial was found on ClinicalTrials.gov in this search.

All of the above is general standard-of-care inference for progressive nonsyndromic SNHL, not evidence specific to DFNA53, and should be labeled as such in any curation use.

13. Prevention

No DFNA53-specific primary, secondary, or tertiary prevention strategy exists. Standard genetic-counseling-based family planning guidance (informing at-risk relatives of the 50% autosomal dominant recurrence risk) is the only prevention-adjacent measure supported by the available literature (GARD summary page).

14. Other Species / Natural Disease

Not applicable/not available. Because the causal gene is unknown, no ortholog, veterinary correlate, or naturally occurring animal disease can be identified or excluded for DFNA53.

15. Model Organisms

None exist. With no causal gene identified, there is no mouse, zebrafish, or other genetic model of DFNA53, no knockout/knock-in resource, and no functional-genomics screen targeting this locus. This is a direct consequence of the locus never having been resolved to a gene, not a gap in searching.

Curation Guidance / Caveats for KB Use

1. This is a locus-only OMIM entry with no gene. Any dismech genetic: block should record the 14q11.2–q12 locus context in notes, but should not invent a gene_term binding — there is none to bind.
2. Single-family evidence. Every clinical/phenotypic claim above traces to one 2006 paper describing one pedigree. Treat prevalence, penetrance, and phenotype-frequency claims accordingly — there is no population-level denominator.
3. The "abnormal vestibular function" GTR/MedGen tag is flagged, not confirmed. Do not cite it as primary-literature evidence without independently verifying it against the full OMIM clinical synopsis or original paper (this search could not access the full OMIM clinical synopsis due to a site-side block).
4. No mechanism section should be written with GO/CL specificity for this entry beyond the caveated inferences in §6 — doing so would fabricate a mechanistic claim the source literature does not support.
5. Per dismech's evidence policy, only PMID:15958501 (and the general-DFNA-context review PMC10296186, cited separately and clearly as general context) should be used as sources; no other primary literature on DFNA53 was found to exist as of this search (September 2026).

Sources

• A novel locus for autosomal dominant non-syndromic deafness, DFNA53, maps to chromosome 14q11.2-q12 (PubMed) — Yan D, Ke X, Blanton SH, Ouyang XM, Pandya A, Du LL, Nance WE, Liu XZ. J Med Genet. 2006 Feb;43(2):170-4. PMID:15958501.
• A novel locus for autosomal dominant non‐syndromic deafness, DFNA53, maps to chromosome 14q11.2‐q12 (PMC)
• OMIM #609965 — DEAFNESS, AUTOSOMAL DOMINANT 53; DFNA53
• Autosomal Dominant Non-Syndromic Hearing Loss (DFNA): A Comprehensive Narrative Review (PMC10296186) — Aldè M, Cantarella G, Zanetti D, Pignataro L, La Mantia I, et al. Audiology Research 2023;13(6):1616 (used only for general DFNA-class context and the DFNA53 locus-table entry).
• Hereditary Hearing Loss Homepage — Autosomal Dominant Nonsyndromic Hearing Loss table
• GARD — Autosomal dominant nonsyndromic hearing loss 53
• NCBI GTR — Autosomal dominant nonsyndromic hearing loss 53 (MedGen C1864957)
• MONDO:0012380 (OLS)

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

• PMID:15958501: "the critical region for DFNA53 contains the gene for DFNA9 [COCH] but does not overlap with the regions for DFNB5, DFNA23, or DFNB35... screening of the COCH gene, BOCT (SLC22A17), EFS, and HSPC156 (STXBP6) within the DFNA53 interval did not identify the cause for deafness in this family"
• closest text in source: "The critical region for DFNA53 contains the gene for DFNA9 but does not overlap with the regions for DFNB5, DFNA23, or DFNB35"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0012380 (4 mentions) - the report calls it "MONDO", "OLS"; MONDO calls it autosomal dominant nonsyndromic hearing loss 53
• UBERON:0001846 (1 mention) - the report calls it "cochlea"; UBERON calls it internal ear

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0008625 (1 mention) - the report calls it "Bilateral profound sensorineural hearing impairment"; HP calls it Severe sensorineural hearing impairment

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0012380 - called "MONDO", "OLS"